Finally, we validated Pax5 expression in tissue microarrays (TMAs) derived from prostate cancer patient derived xenografts (PDX) (LuCaP series) and from metastatic CRPC (mCRPC) tissues obtained from Prostate Cancer Biorepository Network (PCBN). Here, PAX5 is linked to prostate carcinoma.